Sign in
Taking people in United StatesPhase 3

Long-term follow-up of gene therapy for hemophilia A or B

Follows people with hemophilia A or B after earlier gene therapy treatment.

Key facts

Who runs it
Pfizer
Where
Indianapolis, Madison, New York, Philadelphia, Rancho Cordova, Sacramento, San Francisco, Seattle, and Tampa, United StatesSee the 14 sitesAlso in 12 other countries, 24 sites
Trial code
Registry title
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Status
Recruiting
Phase
Phase 3
People taking part
173 people, planned
Started
28 Dec 2022
Expected to end
25 Feb 2040
Type of study
Interventional, 2 groups
Treatments tested
  • Testing of hepatic AAV Vector integration
Record updated
7 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with hemophilia A or B who already received giroctocogene fitelparvovec or fidanacogene elaparvovec in an earlier Pfizer-sponsored study. It follows their long-term safety and results.

Age
18 years or older
Sex
Men only
Disease stage
Hemophilia A or hemophilia B
Earlier treatment
Must have received giroctocogene fitelparvovec or fidanacogene elaparvovec in a Pfizer-sponsored study (C0371002, C0371003, C0371005, C3731001, C3731003).

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • -Only participants who received investigational giroctocogene fitelparvovec or fidanacogene eleparvovec and were enrolled in a Pfizer-sponsored study (C0371002, C0371003, C0371005, C3731001, C3731003) are eligible

Who cannot take part

  • -None

Where in United States

Also in 12 other countries, 24 sites

  • Innovative Hematology, Inc.Indianapolis, United StatesTaking people
  • Mississippi Center for Advanced MedicineMadison, United StatesNo longer taking part
  • Cornell University||Joan & Sanford I. Weill Medical CollegeNew York, United StatesTaking people
  • Weill Cornell Medical College-New York Presbyterian HospitalNew York, United StatesTaking people
  • The Childrens Hospital of Philadelphia Division of HematologyPhiladelphia, United StatesTaking people
  • The Regents of the University of California||UC Davis HealthRancho Cordova, United StatesTaking people
  • UC Davis Ambulatory Care ClinicSacramento, United StatesTaking people
  • UC Davis HealthSacramento, United StatesTaking people
  • UC Davis Hemophilia Treatment CenterSacramento, United StatesTaking people
  • UC Davis Medical CenterSacramento, United StatesTaking people
  • UCSF Outpatient Hematology ClinicSan Francisco, United StatesTaking people
  • Washington Institute for CoagulationSeattle, United StatesTaking people
  • The University of South Florida Board of TrusteesTampa, United StatesTaking people
  • USF Health Morsani Center for Advanced HealthcareTampa, United StatesTaking people

About the trial

What the trial wants to find out

A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.

The 2 groups in the trial

  • Hemophilia A / giroctocogene fitelparvovecOther group

    Participants have received treatment with giroctocogene fitelparvovec in a previous study and are not receiving any investigational product in this study

    Treatment: Testing of hepatic AAV Vector integration

  • Hemophilia B / fidanacogene elaparvovecOther group

    Participants have received treatment with fidanacogene elaparvovec in a previous study and are not receiving any investigational product in this study

    Treatment: Testing of hepatic AAV Vector integration

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY
Plain-language title
Long-term follow-up of gene therapy for hemophilia A or BGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
7 October 2026